Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: To analyze clinical characteristics of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA), especially in patients with poor prognosis. Methods: Seventy-seven RA patients with ILD and 231 age, sex, and disease duration- matched RA patients without ILD were enrolled in this retrospective study. Epidemiologic, clinical, and laboratory information were obtained through a medical chart review. Logistic regression analysis was used to estimate the risk of mortality in RA patients with ILD. Results: Compared to the RA without ILD group, the RA with ILD group had significantly higher titers of rheumatoid factor and the anti-cyclic citrullinated peptide (p = 0.001 for both), higher levels of C-reactive protein (CRP) at the time of RA diagnosis (p = 0.014), and a higher erythrocyte sedimentation rate (p = 0.022) and CRP levels (p < 0.001) throughout the 10-year follow-up period. These patients also received a higher mean daily dose of corticosteroids (p < 0.001). In the subgroup analysis of RA patients with ILD, 28 patients (36.4%) died during follow-up. Multivariate analysis revealed that older age at the time of ILD diagnosis was significantly associated with mortality. Usual interstitial pneumonia (UIP) subtype on high-resolution computed tomography (HRCT) was also suggested as a poor prognostic factor. Conclusions: The survival of RA patients with ILD is adversely affected by age at the time of ILD diagnosis. RA-ILD patients diagnosed after age 65 or with a UIP subtype on HRCT may have a poor prognosis.
Abstract
Background/Aims: To analyze clinical characteristics of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA), especially in patients with poor prognosis. Methods: Seventy-seven RA patients with ILD and 231 age, sex, and disease duration- matched RA patients without ILD were enrolled in this retrospective study. Epidemiologic, clinical, and laboratory information were obtained through a medical chart review. Logistic regression analysis was used to estimate the risk of mortality in RA patients with ILD. Results: Compared to the RA without ILD group, the RA with ILD group had significantly higher titers of rheumatoid factor and the anti-cyclic citrullinated peptide (p = 0.001 for both), higher levels of C-reactive protein (CRP) at the time of RA diagnosis (p = 0.014), and a higher erythrocyte sedimentation rate (p = 0.022) and CRP levels (p < 0.001) throughout the 10-year follow-up period. These patients also received a higher mean daily dose of corticosteroids (p < 0.001). In the subgroup analysis of RA patients with ILD, 28 patients (36.4%) died during follow-up. Multivariate analysis revealed that older age at the time of ILD diagnosis was significantly associated with mortality. Usual interstitial pneumonia (UIP) subtype on high-resolution computed tomography (HRCT) was also suggested as a poor prognostic factor. Conclusions: The survival of RA patients with ILD is adversely affected by age at the time of ILD diagnosis. RA-ILD patients diagnosed after age 65 or with a UIP subtype on HRCT may have a poor prognosis.
참고문헌 (24)
- Kim EJ, "Rheumatoid arthritis-associated interstitial lung disease : the relevance of histopathologic and radiographic pattern", Chest, 136, pp.1397~1405 (2009)
- O’Dwyer DN, "Rheumatoid arthritis(RA)associated interstitial lung disease(ILD)", Eur J Intern Med, 24, pp.597~603 (2013)
- Mori S, "Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis", Respir Med, 106, pp.1591~1599 (2012)
- Park JH, "Prognosis of fibrotic interstitial pneumonia : idiopathic versus collagen vascular disease-related subtypes", Am J Respir Crit Care Med, 175, pp.705~711 (2007)
- Kim EJ, "Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease", Eur Respir J, 35, pp.1322~1328 (2010)
- Fischer A, "Interstitial lung disease in connective tissue disorders", Lancet, 380, pp.689~698 (2012)
- Schoe A, "Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab", Arthritis Rheum, 55, pp.157~159 (2006)
- Perez-Alvarez R, "Interstitial lung disease induced or exacerbated by TNF-targeted therapies : analysis of 122 cases", Semin Arthritis Rheum, 41, pp.256~264 (2011)
- Arnett FC, "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", Arthritis Rheum, 31, pp.315~324 (1988)
- Travis WD, "An official American Thoracic Society", European Respiratory Society statement : update of the international multidisciplinary classification of the idiopathic interstitial pneumonias, 2013, pp.188, 733~748
- Giles JT, "Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease", Ann Rheum Dis, 73, pp.1487~1494 (2014)
- Zhu J, "A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity", J Rheumatol, 41, pp.1282~1289 (2014)
- Shachor Y, "Increased incidence of pulmonary tuberculosis in chronic interstitial lung disease", Thorax, 44, pp.151~153 (1989)
- Silva I, "Assessment of erythrocyte sedimentation rate(ESR)and C-reactive protein(CRP)on rheumatoid arthritis activity prediction", Acta Reumatol Port, 35, pp.456~462 (2010)
- Koduri G, "Interstitial lung disease has a poor prognosis in rheumatoid arthritis : results from an inception cohort", Rheumatology(Oxford), 49, pp.1483~1489 (2010)
- Liu X, "Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?", Arthritis Care Res (Hoboken), 65, pp.1375~1380 (2013)
- Mortensen RF, "C-reactive protein, inflammation, and innate immunity", Immunol Res, 24, pp.163~176 (2001)
- Ohtsuka T, "Serum interleukin-6 level is reflected in elevated high-sensitivity C-reactive protein level in patients with systemic sclerosis", J Dermatol, 37, pp.801~806 (2010)
- Chan E, "Interstitial lung disease in rheumatoid arthritis : a review", Arthritis Res UK, 3, pp.1~9 (2013)
- Assayag D, "Predictors of mortality in rheumatoid arthritis-related interstitial lung disease", Respirology, 19, pp.493~500 (2014)
- Migita K, "Predictors of mortality in patients with interstitial lung disease treated with corticosteroids : results from a cohort study", Medicine(Baltimore), 93, pp.e175~ (2014)
- Olson AL, "Rheumatoid arthritis-interstitial lung disease-associated mortality", Am J Respir Crit Care Med, 183, pp.372~378 (2011)
- Saag KG, "Rheumatoid arthritis lung disease : determinants of radiographic and physiologic abnormalities", Arthritis Rheum, 39, pp.1711~1719 (1996)
- Hudson M, "Immunosuppression for interstitial lung disease in systemic sclerosis: novel insights and opportunities for translational research", J Cell Commun Signal, 6, pp.187~190 (2012)